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Elevated plus-mazeSystemic administration of cannabidiol (CBD), a non-psychotomimetic compound from Cannabis sativa,
attenuates the cardiovascular and behavioral responses to restraint stress. Although the brain structures
related to CBD effects are not entirely known, they could involve brainstem structures responsible for
cardiovascular control. Therefore, to investigate this possibility the present study veriﬁed the effects of CBD
(15, 30 and 60 nmol) injected into the cisterna magna on the autonomic and behavioral changes induced by
acute restraint stress. During exposure to restraint stress (1 h) there was a signiﬁcant increase in mean
arterial pressure (MAP) and heart rate (HR). Also, 24 h later the animals showed a decreased percentage of
entries onto the open arms of the elevated plus-maze. These effects were attenuated by CBD (30 nmol). The
drug had no effect on MAP and HR baseline values. These results indicate that intracisternal administration of
CBD can attenuate autonomic responses to stress. However, since CBD decreased the anxiogenic
consequences of restraint stress, it is possible that the drug is also acting on forebrain structures.D, cannabidiol; EPM, elevated
PAP, pulsate arterial pressure.
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Cannabidiol (CBD) is a component of Cannabis sativawhich lacks the
psychotomimetic effects of its major constituent, Δ9-tetrahydrocan-
nabinol (Δ9-THC) (Zuardi, 2008). CBD has shown several potential
therapeutic effects (Mechoulam et al., 2002) such as antipsychotic
(Zuardi et al., 2006), anticonvulsant (Carlini and Cunha, 1981; Cunha et
al., 1980), neuroprotective (Iuvone et al., 2009) and anti-compulsive
(Casarotto et al., 2010). Additionally, preclinical and clinical studies
indicate that CBD has potential therapeutic activity as an anxiolytic
(Bhattacharyya et al., 2010; Crippa et al., 2004; Fusar-Poli et al., 2010;
Guimaraes et al., 1990; Moreira et al., 2006). Supporting these studies
we have recently observed that systemic administration of CBD
attenuates the behavioral and cardiovascular responses induced by
aversive situations such as contextual fear conditioning and acute
restraint stress (Resstel et al., 2006; Resstel et al., 2009). Acute restraint
is an unavoidable stress situation that elicits blood pressure and heartrate (HR) increases (Tavares and Correa, 2006; Tavares et al., 2009).
These responses are associated with neuronal activation of forebrain
and brainstem structures involved in cardiovascular control (Bhatnagar
et al., 1998; Hsu et al., 2007). In addition, restraint stress reduces
exploratoryactivity inboth theopen-ﬁeldandopenarmsof the elevated
plus-maze (EPM)24 h later. These behavioral changes are attenuatedby
anxiolytic drugs (Kennett et al., 1985; Kennett et al., 1987; Guimarães
et al., 1993; Padovan and Guimaraes, 2000).
Anxiolytic effects of CBD have also been observed after direct drug
microinjections into thebednucleus of the stria terminalis (Gomes et al.,
2010; Gomes et al., 2011), dorsal periaqueductal gray (Campos and
Guimaraes, 2008; Soares et al., 2010) and medial prefrontal cortex
(Lemos et al., 2010). Little is known, however, about the possible
involvement of central cardiovascular regulatory centers, particularly, in
brainstem structures, in CBD anti-stress effects.
Diverse studies have employed the direct administration of drugs
into the cisterna magna to investigate a possible involvement of
brainstem nuclei on drug-induced autonomic responses (Damaso et al.,
2007; Horiuchi et al., 2005; Oliva et al., 2010). Considering that restraint
stress induces the activation of several brainstem structures (Pacak and
Palkovits, 2001), the aim of the present study was to investigate the
effects of intracisternal injection of CBD on the cardiovascular responses
induced by restraint stress. In addition,we also investigated thepossible
effects of CBD on stress behavioral consequences observed 24 h after
restraint.
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2.1. Animals
MaleWistar rats weighing 250–270 gwere housed in groups of four
per cage (41×33×17cm) in a temperature-controlled room(24±1 °C)
under standard laboratory conditions, free access to food andwater and
a 12 h light/dark cycle (lights on at 06:30 A.M.). Experiments were
performed during the morning period. Procedures were conducted in
conformity with the Brazilian Society of Neuroscience and Behavior
guidelines for the care and use of laboratory animals, which are in
compliance with international laws and politics. The Institution's
Animal Ethics Committee approved the housing conditions and
experimental procedures (process number: 83/2005).
2.2. Stereotaxic surgery
Seven days before the experiment the rats were anesthetized with
2,2,2-tribromoethanol (250 mg/kg i.p., Sigma-Aldrich, USA) andﬁxed in
a stereotaxic frame (Stoelting, USA). After scalp anesthesia with 2%
lidocaine, the skull, thebregmaand lambdawere surgically exposed and
the incisor bar adjusted to a ﬂat skull position. The muscles were
retracted from the occipital bone by blunt dissection to allowplacement
of a vertical guide cannula aimed at the cisterna magna. A small
craniotomy was performed from the occipital notch to 1 mm dorsal to
the atlanto-occipital membrane using a dental drill. A stainless steel
guide cannula (22 G) was implanted aiming at the cisterna magna
(antero-posterior=−14.5 mm from bregma; lateral=0.0 mm from
the medial suture, vertical=−7.9 mm from the skull, Paxinos and
Watson, 1997). The cannula was ﬁxed to the skull with dental cement
and a metal screw. An obturator inside the guide cannula prevented
obstruction. After surgery, the animals received a polyantibiotic
(Pentabiotico®, FortDodge, Brazil) and anonsteroidal anti-inﬂammatory
(Banamine®, Schering Plough, Brazil).
2.3. Measurement of cardiovascular responses and restraint stress
For mean arterial pressure (MAP) and heart rate (HR) recording the
rats were anesthetized with 2,2,2-tribromoethanol (250 mg/kg i.p.). A
catheter (a 4 cm PE-10 segment heat-bound to a 13 cm PE-50 segment,
Clay Adams, USA) was implanted into the femoral artery. The catheter
was tunneled under the skin and exteriorized on the animal's dorsum,
allowing cardiovascular recordings from conscious animals.
Cardiovascular responseswere evaluated 24 hafter surgery. Animals
were transferred from the animal room to the experimental room in
their home cages where they remained undisturbed for 1 h. Following
this adaptation period, the arterial cannula was connected to a pressure
transducer and the pulsate arterial pressure (PAP) was recorded using
anHP-7754Aampliﬁer (Hewlett Packard,USA) andanacquisitionboard
(MP-100A, Biopac Systems Inc, USA) connected to a personal computer.
Both MAP and HR values were derived from PAP recordings and were
processed online. Immediately after the intracisternal injections, a
10 min baseline recording was performed followed by a 60 min
restraint period in a plastic cylindrical restraint tube (diame-
ter=6.5 cm, length=15 cm), ventilated by holes (1 cm diameter)
which comprised approximately 20% of the tube surface. The rats
returned to their home cages immediately after this restraint period.
Each rat was submitted to only a single restraint session to avoid stress
tolerance (Guimarães et al., 1993).
2.4. Drugs
CBD (kindly supplied by THC Pharm, Germany) was dissolved in
grape seed oil (100%, Campos and Guimaraes, 2008), whichwas used as
vehicle. The pH of grape seed oil and CBD solutions is about 7.0. The
solutions were prepared immediately before the tests.2.5. Intracisternal injections
Seven days after surgery the animalswere randomly assigned to one
of the treatment groups. Intracisternal injections were performed in
non-handled unrestrained rats in accordance with a previous study
(Oliva et al., 2010). Intracisternal injections were performedwith a thin
dental needle (33 G; Small Parts, USA) introduced through the guide
cannula until its tip was 0.8 mm below the cannula end, connected to a
10 μL syringe (7001 KH,Hamilton Co., USA) through a PE-10 tubing. The
injection needle was carefully inserted into the guide-cannula, and a
volume of 1 μL of vehicle or the CBD solution was injected at the rate of
2 μL/min with the help of an infusion pump (Kd Scientiﬁc Inc., USA).
A polyethylene tubing (PE-10) was interposed between the upper end
of the dental needle and the syringe. Successful infusions were
conﬁrmed by the displacement of an air bubble inside the polyethylene
tubing. At the endof injection, the needlewas kept in place for 45 to 60 s
to avoid the drug reﬂux.
2.6. Experimental design
2.6.1. Experiment 1: effects of intracisternal injections of CBD on
cardiovascular responses to acute restraint stress
Rats (n=6/group) received intracisternal injections of vehicle
(grape seed oil) or previously reported effective doses of CBD (15, 30
or 60 nmol) (Campos and Guimaraes, 2008; Lemos et al., 2010).
Immediately thereafter, a 10 min of baseline cardiovascular recording
was performed followed by the 60 min restraint period.
2.6.2. Experiment 2: effects of intracisternal injections of CBD (30 nmol) on
the anxiogenic consequences of restraint stress
Rats (n=7 and 8)were injected into the cisternamagnawith either
vehicle or CBD(30 nmol) and, 10 min after that, restrained throughout a
60 min period. Thereafter, the rats were housed as described in item2.1
and, 24 h later, tested in the EPM. Unrestrained control rats were
subjected to similar treatments with vehicle or CBD (n=6 and 7).
2.7. Elevated plus-maze (EPM)
TheEPMtestwas conductedasdescribedbyPadovanandGuimaraes
(2000). Brieﬂy, the apparatus consisted of two opposite wooden open
arms (50×10 cm), crossed at right angle by two arms of the same
dimensions enclosed by 40-cm high walls with no roof. The maze was
set up 50 cm above the ﬂoor and had a 1-cm high Plexiglas edge
surrounding the open arms so as to prevent the rat fall. The apparatus
was located in a sound-attenuated, temperature-controlled (24±1 °C)
room lit by a 40W ﬂuorescent light placed 3 m away from the EPM. Rat
behaviors were ﬁlmed throughout 5 min and analyzed off-linewith the
aid of Any-Maze software (Stolelting, USA). At the endof trials, themaze
was cleaned up with an alcohol solution.
2.8. Histology
At the end of the experiments the rats were anesthetized with
urethane (1.25 g/kg i.p., Sigma-Aldrich, USA) and injected into the
cisternamagnawith 1 μL of 1% Evan's Blue dye. After that, the chest was
opened, thedescending aorta occluded, the right atriumsevered and the
brain perfusedwith 10% formalin through the left ventricle. The brain of
rats was removed and examined for staining.
2.9. Statistical analysis
MAP and HR values were continuously recorded for 10 min before
and 60 min during the exposure to restraint stress. Datawere expressed
as means±SEM. of MAP or HR changes (respectively ΔMAP and ΔHR)
sampled at 2.5 min intervals. Points sampled during the 10 min before
restraintwere used as control baseline value.MAP andHRchangeswere
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and time as repeated measurement. Moreover, one-way ANOVA
followed by Bonferroni's post-hoc test was used to compare the effect
of the treatments on the restraint-evoked MAP and HR maximum
responses.
The percentage of entries and time spent in the open arms
(100×open/(open+enclosed)) during the 5-min sessions in the EPM
were calculated for eachanimal. These resultswere analyzedby two-way
ANOVAusing condition (restraint or no restraint) and treatment (CBD or
vehicle) as main factors. Post-hoc analysis was performed using the
Bonferroni test. Differences were considered signiﬁcant at Pb0.05 level.
3. Results
3.1. Experiment 1: effects of intracisternal injections of CBD on cardiovascular
responses to restraint stress
Groups did not differ in either theMAP or HR baseline levels before
restraint stress (Table 1).
Acute restraint induced amarked and sustained increase in both the
ΔHR (F27,560=23.94, Pb0.001) and ΔMAP (F27,560=18.08, Pb0.001).
However, although the treatment effects differed signiﬁcantly (ΔMAP:
F3,560=55.85, Pb0.001 and ΔHR: F3,560=55.75, Pb0.001), there were
no drug-treatment signiﬁcant interactions among groups. Rats treated
with 30 nmol CBD showedΔMAP (6.95±3.49) andΔHR (32.74±6.50)
responses to restraint stress signiﬁcantly smaller (ΔMAP: F3,20=4.66,
Pb0.05 and ΔHR: F3,20=4.80, Pb0.05) as compared to vehicle-treated
rats (ΔMAP: 17.10±1.87 and ΔHR: 60.34±5.49) (Fig. 1B and D).
Remaining doses were ineffective.
Typical experimental recordings showing the effects of intracis-
ternal injections of CBD (30 nmol) on cardiovascular responses
observed during acute restraint can be seen in Fig. 2.
3.2. Experiment 2: effects of intracisternal injections of CBD (30 nmol) on
the anxiogenic consequences of restraint stress
EPM performance differed signiﬁcantly among groups (F3,24=4.98,
Pb0.01). Vehicle-treated rats showed a signiﬁcant reduction in the
percentage of open arms entries 24 h after the stress (Bonferroni's test,
Pb0.05; Fig. 3). CBD-treated stressed groupdidnot differ fromeither the
CBD- or the vehicle-treated non-stressed groups. Therewas no effect on
the percentage of time spent in the open arms (F3,24=1.91, PN0.05).
Additionally, no effects on number of enclosed arms entries were found
(F3,24=0.53, PN0.05).
4. Discussion
Our results showed that acute exposure to restraint stress induced
a marked and sustained increase in MAP and HR. The stressed animals
also presented a decrease in the percentage of open arms entries in
the EPM 24 h after restraint. Even if a similar effect in the percentage
of time spent in these arms did not reach signiﬁcance level, the lack of
any change in the number of enclosed arm entries points to a speciﬁcTable 1
Basal values of the MAP and HR in vehicle and CBD treated rats.
Group MAP (mm Hg) HR (bpm)
Vehicle 97±4 364±7
CBD 15 nmol 98±2 363±7
CBD 30 nmol 100±4 368±8
CBD 60 nmol 101±2 349±8
F3,20=0.31 F3,20=1.24
The values in the table represent the means±SEM, One-way ANOVA (n=6/group).
CBD, cannabidiol; HR, heart rate; MAP, mean arterial pressure.stress-induced reduction in open arm exploration, which is usually
interpreted as an anxiogenic effect (File, 1992). These results agree
with previous studies that have investigated the autonomic and
behavioral consequences of restraint stress (Barron and Van Loon,
1989; Irvine et al., 1997; McDougall et al., 2000; Guimarães et al.,
1993; Kennett et al., 1985; Kennett et al., 1987; Padovan and
Guimaraes, 2000). The cardiovascular and behavioral effects of
restraint stress were attenuated by intracisternal administration of
CBD. Thus, it is not possible to rule out the possibility that the
attenuated cardiovascular response to restraint after CBD treatment
may be related to the reduced aversive response.
Conﬁrming previous reports (McQueen et al., 2004; Resstel et al.,
2006; Resstel et al., 2009), CBD did not induce any signiﬁcant change on
MAP andHR baseline values. This suggests that CBDmay act speciﬁcally
on stress-activated cardiovascular pathways. Similar results have been
observed after systemic administration of this compound (Resstel et al.
2009).Moreover, as described in other studies (Campos andGuimaraes,
2008; Guimaraes et al., 1990; Lemos et al., 2010; Zanelati et al., 2010),
CBD had non-linear effects on cardiovascular parameters. These curves
are commonly observed with cannabinoids (Viveros et al., 2005) and
their mechanisms could reﬂect the complex pharmacology of these
compounds involving, for example, the activation of TRPV1 receptors at
higher concentrations (Campos and Guimarães, 2009).
Acute restraint stress induces signiﬁcant neuronal activation in
importantmedullary areas involved in autonomic control, including the
nucleus of the solitary tract and ventrolateral medulla (Goebel et al.,
2009). Several studies have employed intra-cisterna magna adminis-
tration of drugs to evaluate a possible involvement of the brainstem
nuclei on autonomic responses (Damaso et al., 2007; Horiuchi et al.,
2005; Oliva et al., 2010). Thus, Damaso et al. (2007), using a larger
volume (5 μl) than that of the present study, described that the solution
injected would spread from the dorsal surface, laterally to the ventral
surface of the brainstem.Moreover,Horiuchi et al. (2005) observed that,
following intracisternal injection of 5 μl of dye, the rostral solution
spreading reaches the pons. It is conceivably, therefore, that in our study
CBD could be acting in brainstem regions such as the nucleus of the
tractus solitary and the rostral ventrolateral medulla, two important
medullary areas involved in autonomic control that can play a role in
stress-induced cardiovascular responses (Korte et al., 1992; Mayorov
and Head, 2003). Besides these regions, several others areas of the
central nervous system have also been involved in the cardiovascular
responses associated with stress. They include the septal lateral area
(Kanaya et al., 2003; Kubo et al., 2002); anterior hypothalamic area
(Krout et al., 2005; Kubo et al., 2001); paraventricular nucleus of the
hypothalamus (Busnardo et al., 2010; Tavares et al., 2009), medial
prefrontal cortex (Tavares and Correa, 2006); bed nucleus of stria
terminalis (Crestani et al., 2009) and the medial amygdala (Fortaleza
et al., 2009; Kubo et al., 2004), which are directly connected to
brainstem regions that integrate autonomic and neuroendocrine
responses during stressful situations (Pacak and Palkovits, 2001).
Although CBD has been shown to change neural activity of limbic
areas in humans (Crippa et al., 2004), only recently the brain sites of its
antiaversive effects have started to be investigated in laboratory
animals. CBD injected into the bed nucleus of the stria terminalis, for
example, attenuates behavior and cardiovascular responses induced by
contextual fear conditioning (Gomes et al., 2010), causes anxiolytic-like
effects in the EPM and Vogel conﬂict test (Gomes et al., 2011) and
modulates the parasympathetic component of baroreﬂex (Alves et al.,
2010).Moreover, similar to thebed nucleus of the stria terminalis, intra-
dorsolateral periaqueductal gray andprelimbicmedial prefrontal cortex
administration of CBD induces anxiolytic-like effects (Campos and
Guimaraes, 2008; Lemos et al., 2010).
Diffusion of CBD to these rostral brain regions cannot be ruled out as
an explanation to the present results. Actually, Proescholdt et al. (2000),
using quantitative in vivo autoradiography, showed labeling in the
hypothalamus and brainstem 5 and 10 min after intracistenal injections
Fig. 1. A) Time-course of mean arterial pressure changes (ΔMAP) during restraint in rats treated with CBD (15, 30 or 60 nmol) or vehicle (1 μL). B) Restraint-evoked changes (time 0 to
60 min) in ΔMAP after intracisternal treatment with CBD (15, 30 or 60 nmol) or vehicle. C) Time-course of heart rate changes (ΔHR) during restraint in rats treated with CBD (15, 30 or
60 nmol) or vehicle. D) Restraint-evoked changes (time 0 to 60 min) in ΔHR after intracisternal treatment with CBD (15, 30 or 60 nmol) or vehicle (n=6/group). The animals received
intracisternal injection 10 min before the beginning of the restraint. The arrows indicate the beginning of the restraint period. Data shown represent themeans±SEM. *Pb0.05, compared
to vehicle group; ANOVA followed by Bonferroni's post hoc test.
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tion of drugs have been reported by several studies (Makino et al., 2000;
Martinez et al., 1997; Montkowski et al., 1997; Shestakova et al., 2009).
Nevertheless, previous studies investigating intra-cerebral administra-
tion of CBD into the dorsolateral periaqueductal gray (Campos and
Guimaraes, 2008) and the bed nucleus of the stria terminalis (Gomes et
al., 2010; Gomes et al., 2011) on anxiety models have found anxiolyticFig. 2. Mean arterial pressure (MAP), pulsate arterial pressure (PAP) and heart rate (HR) indiv
treated with vehicle (1 μL) and CBD (30 nmol). The restraint period started at time 0. The animeffects of a 30 nmol dose, with lower doses being ineffective. Since the
injected volumes (0.2 μL) were much smaller than that of the present
study (1 μL) and the behavioral tests were also performed 10 min after
drug administration, it is unlikely that in our work an effective
concentration of CBD could have reached these midbrain and forebrain
structures at the moment of the cardiovascular measurements. Studies
with restraint models, however, have shown that pharmacologicalidual recordings showing the cardiovascular changes evoked by acute restraint in animals
als received intracisternal injection 10 min before the beginning of the restraint.
Fig. 3. Effects in the elevated plus-maze (EPM) of intracisternal injection of vehicle (1 μL)
or CBD (30 nmol) 10 min before a 60 min restraint period. Non-stressed groups
(no restraint) that received vehicle or CBD (30 nmol) were used as control (n=6–8/
group). The EPMtestwasperformed24 hafter the restraint period. Theupperpanel shows
the number of entries into the enclosed arms whereas the lower panel shows the
percentage of entries (white columns) and the time spent (black columns) in the open
arms. Data represent the mean±SEM. *Pb0.05, compared to others groups; ANOVA
followed by Bonferroni's post hoc test.
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anxiogenic consequence (Guimarães et al., 1993). Since CBD was
administered 10 min before the restraint session, the possibility that its
behavioral effects in this study depend on CBD action at the end or after
the stress period remains to be investigated.
The mechanism of action of CBD is not fully understood. It has a low
afﬁnity for cannabinoid receptors (Petitet et al., 1998; Thomas et al.,
1998) but can block the reuptake of endocannabinoid anandamide and/
or itsmetabolismby the enzyme, fatty acid amide hydrolase (Bisogno et
al., 2001). Moreover, CBD may possess agonistic properties at 5-HT1A
receptors (Russo et al., 2005). CBDhas also been found to activate TRPV1
receptors (Bisogno et al., 2001), enhance adenosine signaling through
inhibition of uptake (Carrier et al., 2006) and allosterically modulate
5-HT3 (Yang et al., 2010) and μ- and δ-opioid receptors (Kathmann et al.,
2006). The involvement of these mechanisms in the effects of
intracisternal administration of CBD remains to be tested.
In conclusion, the present study shows that intracisternal adminis-
tration of CBD attenuates the behavioral and cardiovascular responses
induced by acute restraint stress. Additional studies are needed to
investigate the speciﬁc brain regions involved in these effects.
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